Dapagliflozin-Associated Bullous Pemphigoid

Xun Feng¹, Mintong Wei¹, Jishu Li¹, Qingfeng Liu², Min Zou¹, Luyuan Li³, Takashi Hashimoto^{1

4}, Wei Li¹

Affiliations

¹ Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
² West China Hospital, Sichuan University, Chengdu, China.
³ The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
⁴ Department of Dermatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

Xun Feng et al. Int J Dermatol. 2025.

. 2025 Nov 8.

doi: 10.1111/ijd.70159. Online ahead of print.

Xun Feng¹, Mintong Wei¹, Jishu Li¹, Qingfeng Liu², Min Zou¹, Luyuan Li³, Takashi Hashimoto^{1

4}, Wei Li¹

¹ Department of Dermatology & Venerology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China.
² West China Hospital, Sichuan University, Chengdu, China.
³ The First School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, China.
⁴ Department of Dermatology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.

No abstract available

Keywords: bullous pemphigoid; dapagliflozin; direct immunofluorescence; drug‐induced.

References

1. M. D. Sarah, U. P. Priya, I. Laszlo, and W. M. George, “Bullous Pemphigoid in a Patient With a Neuropsychological Disorder and a Possible Novel Drug Trigger: A Case Report and Review of the Literature,” Skin Health Disease 2, no. 4 (2022): ski2‐176.
1. S. Ma, C. Y. Wu, Y. S. Lyu, Y. J. Chou, Y. T. Chang, and C. Y. Wu, “Association Between Sodium‐Glucose Co‐Transporter 2 Inhibitors and Risk of Bullous Pemphigoid in Patients With Type 2 Diabetes: A Nationwide Population‐Based Cohort Study,” Journal of the European Academy of Dermatology and Venereology 36, no. 8 (2022): 1318–1324.
1. V. Outi, J. Jari, H. Laura, and T. Kaisa, “GLP‐1 Analogs and SGLT2 Inhibitors Do Not Increase Risk of Bullous Pemphigoid,” Journal of Investigative Dermatology 141, no. 12 (2021): 2969–2972.
1. L. Jing‐Hui and Z. Ya‐Gang, “The “Entanglement” Between Bullous Pemphigoid and Diabetes Mellitus: A Comprehensive Review and Expert Recommendations,” Expert Review of Clinical Immunology 21, no. 3 (2024): 333–346.
1. M. P. David, W. Ashley, S. Sally, and C. M. John, “False‐Negative Rate of Direct Immunofluorescence on Lower Extremities in Bullous Pemphigoid,” American Journal of Dermatopathology 43, no. 1 (2020): 42–44.